Intarcia Therapeutics
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Intarcia Therapeutics sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Intarcia Therapeutics: 16 sponsored US clinical trials, none currently recruiting.
Intarcia Therapeutics sponsors 16 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 10 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Neoplasms, Hormone-dependent, with 1 trials.
Top-decile sponsor footprint
Intarcia Therapeutics ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (68.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
16 total, page 1 of 1
Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
NCT03060980
Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs
NCT02641899
Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects
NCT02641990
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
NCT02638805
Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects
NCT02320045
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes
NCT01455870
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c
NCT01785771
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650
NCT01455896
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes
NCT01455857
Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus
NCT00943917
Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes
NCT01798264
Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment
NCT00519792
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
NCT00267553
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
NCT00097344
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
NCT00044291
Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer
NCT00010322
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
| Phase 3 | 10 |
Therapeutic Areas
How the Intarcia Therapeutics archive is shaped
16 indexed studies, none listed as recruiting (0% open); 11 completed (69%).
Phase mix: 10 late (III/IV) vs 6 early (I/II) (later-stage heavy).
Top condition: Neoplasms, Hormone-dependent (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Intarcia Therapeutics: archived-pipeline peers nationwide
Peers matched on 16 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Intarcia Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 archived trials
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Intarcia Therapeutics page
16 registered trials is a research-attention snapshot, not an endorsement of Intarcia Therapeutics or any single study.
- None of Intarcia Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Neoplasms, Hormone-dependent is the condition Intarcia Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Neoplasms, Hormone-dependent trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Intarcia Therapeutics pipeline card: 16 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.